Oxford BioMedica is a biopharmaceutical company that specializes in the development and commercialization of gene-based medicines.
Company (IPO / Went public)
Phone: +44 (0) 1865 783 000
Windrush Court
Transport Way
Oxford, OX4 4GA
England, United Kingdom
Total Funding | Date of Last Funding | |
---|---|---|
Oxford BioMedica | $67.8M | May 28, 2019 |
See all 16 competitors |
Per Week | Per Month | Per 6 Months | Per Year | |
---|---|---|---|---|
Rank | Login to see details | |||
Page Views Per Million | Login to see details | |||
Page Views Per User | Login to see details | |||
Reach Per Million | Login to see details |
Investor | Investor Type | Location | Participating Rounds |
---|
Company | Status | Description | Investors |
---|---|---|---|
Minneapolis, Minnesota, United States | IPO / Went public | DiaMedica is a clinical stage biopharmaceutical company primarily focused on the development of recombinant (synthetic) proteins and commercialization of recombinant proteins to treat neurological and kidney diseases. | Login to see details |
Winnipeg, Manitoba, Canada | Alive / Active | Sanomune is a private biotech start-up focused on neurological and autoimmune diseases. The company's technology is based on the repurposing of a safe, oral biological to treat large market indications. Sanomune's lead product, SAN-61, is a potential first-in-class treatment targeting the dual hallmark pathologies of Alzheimer's (AD): amyloid beta plaque deposition and the formation of neurofibrillary tangles. No other known therapy can effectively target both aspects of the disease. Sanomune's ...Show all | Login to see details |
Title | Application Date | Patent Date | Status (Patent / Application) |
---|---|---|---|
Viral vector production system | Dec 19, 2014 | Jan 28, 2020 | Patent |
Catecholamine enzyme fusions | Oct 26, 2012 | Sep 03, 2019 | Patent |
Virus purification | Sep 14, 2015 | Apr 30, 2019 | Patent |
Viral vector | May 07, 2004 | Aug 22, 2017 | Patent |
Method for vector delivery | May 14, 2013 | May 17, 2016 | Patent |